A Case of Hemolytic Uremic Syndome During Interferon-alpha Treatment for Chronic Myelogenous Leukemia.
- Author:
Jai Won CHANG
1
;
Yu Mi KIM
;
Jang Won SEO
;
Kwi Sook CHOI
;
Soo Jin YOO
;
Hyun Sook CHI
;
Chong Woo YOO
;
Su Kil PARK
Author Information
1. Department of Internal Medicine, College of Medicine, University of Ulsan, Seoul, Korea. skpark@amc.seoul.kr
- Publication Type:Case Report
- Keywords:
Interferon-alpha;
Hemolytic uremic syndrome;
Chronic myelogenous leukemia
- MeSH:
Adult;
Anemia, Hemolytic;
Azotemia;
Biopsy;
Bone Marrow;
Diagnosis;
Edema;
Hemolytic-Uremic Syndrome;
Humans;
Interferon-alpha*;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*;
Male;
Necrosis;
Plasmapheresis;
Proteinuria
- From:Korean Journal of Nephrology
2002;21(2):341-347
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Interferon-alpha is an established therapy for the patients with myeloproliferative disease. Unusual immune-mediated side effects have been reported during treatment. Among them, renal and cardiac toxicities are rare complications. Recently we experienced a case of hemolytic uremic syndome found in a 40-year old male undergoing interferon-alpha therapy for chronic myelogenous leukemia, chronic phase. On admission, his chief complaints were generalized edema and azotemia. Bone marrow biopsy revealed transformation into accelerated phase. bcl/abl gene was positive. Peripheral blood smear showed hemolytic anemia. Despite prompt diagnosis, institution of plasmapheresis, and steroid, his renal function did not recover, as expected. Hemolytic uremic syndrome was a chronic form of renal toxicity due to interferon-alpha. In this case, renal function did not recovered to normal level. However, early detection of renal toxicity such as proteinuria or acute tubular necrosis, and the discontinuation of interferon-alpha could achieve the recovery of normal renal function. Therefore, periodic examination of renal function should be performed in the patients with the use of long-term interferon-alpha.
